Samsung to Launch AI-Powered OB-GYN Ultrasound at Society for Maternal-Fetal Medicine Conference
Designed for advanced OB-GYN applications, the Samsung Z20 ultrasound platform reportedly provides a combination of artificial intelligence (AI) tools and enhanced ergonomics.
Offering a variety of artificial intelligence (AI) features to bolster workflow efficiency, Samsung plans to launch the Z20 ultrasound system at the Society for Maternal-Fetal Medicine conference (continuing today through February 1) in Denver.
Samsung noted the Z20 ultrasound’s deep learning feature Live ViewAssist™ provides automated labeling of up to 47 anatomic structures, performs 46 key measurements and facilitates up to a 94 reduction in keystrokes.
The Z20 ultrasound system, which will be launched at he upcoming Maternal-Fetal Medicine conference in Denver, reportedly performs 46 key measurements and provides automatic labeling of 47 anatomic structures for OB-GYN exams, according to Samsung, the developer of the Z20 ultrasound system. (Photo courtesy of Samsung.)
Employing advanced software beamforming, the Z20 ultrasound system offers enhanced diagnostic accuracy, even in cases involving patients with a high body mass index (BMI), according to Samsung. The company added that recent independent testing of the Z20 device found that it met or exceeded all standard ergonomic measurements.
“The Z20 represents a significant technology milestone for both Samsung and the broader ultrasound industry. … (It) also reflects our commitment to breaking the iron triangle of healthcare cost, access, and quality by integrating the Z20 with a digital ecosystem for telesonography, reporting, and fleet management,” noted Tracy Bury, the vice president and head of ultrasound USA and global growth initiatives at Samsung Medison.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
SNMMI: Can Multimodal Monitoring Bolster Outcomes with Pluvicto in Treating mCRPC?
June 22nd 2025Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
GE HealthCare Unveils Enhanced LesionID Pro at SNMMI Conference
Published: June 21st 2025 | Updated: June 21st 2025Emphasizing a zero-click experience, the updated LesionID Pro software, to be introduced at the SNMMI conference, reportedly provides AI-powered automated insights into whole-body tumor burden with PET and SPECT imaging.
